Document is current
Any future updates will be listed below
-
Authors
Jackson, Daniel J.
Bourdin, Arnaud
Blackorby, Allison
Leslie, Anna
Vichiendilokkul, Anna
Howarth, Peter
Karkoszka, Natalia
Fujieda, Shigeharu
Cornet, Marjolein
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04719832 at ClinicalTrials.govnct04718103 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2
https://doi.org/10.1007/s12325-025-03457-4
S135 Twice-yearly depemokimab demonstrates efficacy in patients with asthma across baseline medium- and high-dose ICS subgroups: Phase III SWIFT-1/2 studies
https://doi.org/10.1136/thorax-2025-btsabstracts.141
nct05274750 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2
https://doi.org/10.1007/s12325-025-03457-4
nct05281523 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2
https://doi.org/10.1007/s12325-025-03457-4
Documents that mention this clinical trial
Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2
https://doi.org/10.1007/s12325-025-03457-4
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals
- License Information
-
More Information
Article History
Received: 23 October 2025
Accepted: 26 November 2025
First Online: 29 December 2025
Declarations
:
: Daniel J Jackson has consulted for and received grants from Regeneron, Sanofi and GSK, consulted for and was a member of a Data and Safety Monitoring Board for AstraZeneca, consulted for Areteia, Avillion and Genentech (2022), and received a grant from OM Pharma and DSMB for Upstream Bio. Arnaud Bourdin has received grants from GSK, Boehringer Ingelheim and AstraZeneca; has participated in clinical research projects (as an investigator) with GSK, AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Acceleron, Gossamer, Pfizer, MSD and Sanofi; and has received personal fees for advisory boards and other meetings from GSK, AstraZeneca, Amgen, Regeneron‐Sanofi, Novartis, Celltrion and Chiesi. Allison Blackorby, Anna Leslie, Anna Vichiendilokkul, and Peter Howarth are employees of GSK and hold financial equities in GSK. Natalia Karkoszka is a former employee of GSK and holds financial equities in GSK. Shigeharu Fujieda has been an advisory board member for AstraZeneca, GSK, and Sanofi, and has received speaker fees from Kyorin, Mitsubishi Tanabe, Sanofi, GSK and Taiho. Marjolein Cornet has received speaker fees and participated in advisory board meetings for Regeneron Pharmaceuticals Inc., Sanofi Genzyme, GSK, ALK, Chiesi and Stallergenes Greer.
: All studies were conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable national and international laws and regulations. All patients were recruited after obtaining written informed consent.
